EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

56P Real-world outcomes of targeted therapy and immunotherapy in patients with anaplastic thyroid carcinoma

I. Micheletto, S. Llop Serna, P. Jimenez Labaig, L. Cheng, K.J. Harrington, K.H.H. Wong, K. Newbold

ESMO Rare Cancers · 2026-03 · 5 · 100262

DOI: 10.1016/j.esmorc.2026.100262 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ESMO Rare Cancers, 2026-03. Verfasst von I. Micheletto und 6 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Micheletto, I., Serna, S. L., Labaig, P. J., Cheng, L., Harrington, K., Wong, K., & Newbold, K. (2026). 56P Real-world outcomes of targeted therapy and immunotherapy in patients with anaplastic thyroid carcinoma. ESMO Rare Cancers, 5, 100262. https://doi.org/10.1016/j.esmorc.2026.100262

Vancouver

Micheletto I, Serna SL, Labaig PJ, Cheng L, Harrington K, Wong K, et al. 56P Real-world outcomes of targeted therapy and immunotherapy in patients with anaplastic thyroid carcinoma. ESMO Rare Cancers. 2026;5:100262. doi:10.1016/j.esmorc.2026.100262

BibTeX
@article{Micheletto2026,
  author = {Micheletto, I. and Serna, S. Llop and Labaig, P. Jimenez and Cheng, L. and Harrington, K.J. and Wong, K.H.H. and Newbold, K.},
  title = {56P Real-world outcomes of targeted therapy and immunotherapy in patients with anaplastic thyroid carcinoma},
  journal = {ESMO Rare Cancers},
  year = {2026},
  volume = {5},
  pages = {100262},
  doi = {10.1016/j.esmorc.2026.100262}
}
Kostenlos starten →